Stealth BioTherapeutics announced that the company will have a poster presentation with a live discussion at the upcoming 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting, which is being held May 1-7, 2021. The poster showcases data that are consistent with elamipretide’s mechanism of action and provides further support for the company’s design of ReCLAIM-2, Stealth’s phase 2 trial focused on earlier stages of geographic atrophy which recently completed enrollment. The presentations will be available to conference attendees via the conference website.
The presentation details are as follows:
- Title: Association of Ellipsoid Zone Integrity and Treatment Response in Non-Neovascular AMD Treated with Subcutaneous Elamipretide
- Date and Time: May 1, 3:15 p.m. – 4:45 p.m. ET with live discussion from 4:45 p.m. – 5:00 p.m. ET.
ReCLAIM-2 is a phase 2 randomized, double-masked, placebo-controlled study to evaluate the efficacy and pharmacokinetics of elamipretide in patients with dry age-related macular degeneration (AMD) with geographic atrophy (GA). The ReCLAIM-2 study completed enrollment with 176 patients. The primary endpoint of the 48-week study will measure the low-luminance best-corrected visual acuity, which assesses visual function under low light conditions meant to represent dusk or indoor (artificial) lighting. Secondary functional endpoints are change in low-luminance reading acuity and best-corrected visual acuity (BCVA). Secondary imaging endpoints assessing the rate of progression of the disease include GA area as measured by fundus autofluorescence and optical coherence tomography.